Skip to main content
BIOVENTIX PLC logo

BIOVENTIX PLC — Investor Relations & Filings

Ticker · BVXP ISIN · GB00B4QVDF07 LEI · 213800225MHX7LZQY108 IL Manufacturing
Open in API
Filings indexed 211 across all filing types
Latest filing 2014-10-07 Earnings Release
Country GB United Kingdom
Listing IL BVXP

About BIOVENTIX PLC

https://www.bioventix.com/

Bioventix PLC is a biotechnology company that specializes in the development, creation, and commercial supply of high-affinity sheep monoclonal antibodies (SMAs). These antibodies are utilized by global diagnostic companies as critical components in clinical diagnostic platforms, particularly for blood testing immunoassays. The company's portfolio supports a variety of applications, including diagnostics for cardiovascular conditions (troponin), oncology, and neurodegenerative diseases such as Alzheimer's. In addition to its core antibody products, Bioventix also provides ELISA kits for monitoring exposure to industrial pollutants and offers contract services for the development of new SMAs for healthcare organizations.

Recent filings

Filing Released Lang Actions
BIOVENTIX PLC - Preliminary results for the year ended 30 June 2014
Earnings Release Classification · 100% confidence The document is explicitly titled "BIOVENTIX PLC - Preliminary results for the year ended 30 June 2014". It contains a full Profit and Loss Account, Balance Sheet, and Cash Flow Statement for the year, along with management commentary on performance and dividends. This structure and content strongly indicate a comprehensive annual financial report. Although it uses the term 'Preliminary results', the inclusion of audited results (as stated in the text: "The Company announces its audited results...") and the full set of financial statements for a full fiscal year (ended June 30) aligns best with the definition of an Annual Report (10-K), even if it might be a preliminary version released before the final filing or an equivalent annual filing outside the US SEC system. Given the options, '10-K' is the closest fit for a comprehensive annual financial report. FY 2014
2014-10-07 English
BIOVENTIX PLC - Bioventix Announces License Agreement
Legal Proceedings Report Classification · 99% confidence The document is a press release from Bioventix plc, dated August 20, announcing the signing of a license agreement with DIAsource ImmunoAssays S.A. regarding intellectual property, specifically a European patent opposition. This announcement details a significant business event, a legal/IP resolution, and its impact on the company's operations. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a standard regulatory filing like a director's dealing (DIRS) or major shareholding change (MRQ). Since it concerns a significant legal/IP matter resolution that impacts business operations, it most closely aligns with a Legal Proceedings Report (LTR) or a general Regulatory Filing (RNS). Given the specific nature of resolving a patent dispute, LTR is a strong candidate, but since it is framed as a business update resolving a prior legal action, and it is a general press release format, RNS (Regulatory Filings - the fallback for miscellaneous announcements) is also applicable. However, the core content is the resolution of a legal/IP dispute, which fits the description of 'Legal Proceedings Report' (LTR) better than the general 'RNS' fallback, as it directly addresses the outcome of a legal matter. Considering the options, LTR (Legal Proceedings Report) covers updates on significant lawsuits or regulatory actions. Resolving a patent opposition falls under this umbrella. The document length is short (2787 chars), but it is the substance of the announcement itself, not an announcement *of* another report, so RPA/RNS based on the 'MENU VS MEAL' rule is not triggered for the report itself. Final determination: The resolution of a patent dispute is best classified as LTR.
2014-08-21 English
BIOVENTIX PLC - Admission to AIM
Regulatory Filings Classification · 95% confidence The document is a press release announcing the 'Admission to AIM' (London Stock Exchange's Alternative Investment Market) for Bioventix plc. It details the transition from trading on ISDX to AIM and mentions the role of the Nominated Adviser and Broker. This type of announcement, which concerns the listing status and trading venue of the company's shares, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or corporate actions (like DIV, SHA). Since it is a general regulatory announcement regarding market status and does not fit the definitions for AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DIRS, ER, SR, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS, the most appropriate fallback category is Regulatory Filings (RNS). The document length is short (2549 chars), but it is the primary announcement itself, not an announcement *of* another report.
2014-04-29 English
Full accounts made up to 2013-06-30
Regulatory Filings
2013-10-23 English
Full accounts made up to 2012-06-30
Regulatory Filings
2012-10-31 English
Full accounts made up to 2011-06-30
Regulatory Filings
2011-11-18 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.